4D Molecular Therapeutics... (FDMT)
2.89
-0.39 (-11.89%)
At close: Apr 03, 2025, 3:59 PM
3.02
4.50%
After-hours: Apr 03, 2025, 06:39 PM EDT
4D Molecular Therapeutics Inc. Revenue Breakdown
| Quarter | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration And License Revenue Revenue | 3K | 28K | 0 | 20.01M | 239K | 298K | 1.25M | 500K | 162K | 1.22M | 12K | 64K | 14.58M | 2M |
| Collaboration And License Revenue Revenue Growth | -89.29% | n/a | -100.00% | +8271.55% | -19.80% | -76.10% | +149.40% | +208.64% | -86.71% | +10058.33% | -81.25% | -99.56% | +629.00% | n/a |
Revenue by Geography
| Quarter | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|
| Netherlands Revenue | 567K | 3.09M | 736K | 742K |
| Netherlands Revenue Growth | -81.67% | +320.38% | -0.81% | n/a |
| United States Revenue | 20.16M | 35K | 121K | -27K |
| United States Revenue Growth | +57488.57% | -71.07% | -548.15% | n/a |
Operating Expense Breakdown
| Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 12.65M | 10.6M | 8.7M | 10.61M | 9.11M | 8.79M | 7.99M | 8.47M | 8.05M | 8.17M | 8.23M | 7.33M | 8.19M | 6.95M | 5.54M | 6.84M | 3.68M | 3.06M | 3.65M | 5.96M | 3.05M | 2.44M | 2.44M | 1.98M | 1.98M | 1.1M | 1.1M |
| Selling, General, and Administrative Revenue Growth | +19.34% | +21.85% | -17.96% | +16.38% | +3.65% | +10.00% | -5.61% | +5.11% | -1.36% | -0.78% | +12.31% | -10.49% | +17.75% | +25.44% | -18.96% | +85.77% | +20.25% | -16.20% | -38.68% | +95.25% | +24.98% | n/a | +23.05% | n/a | +80.57% | n/a | n/a |
| Research and Development Revenue | 38.48M | 31.86M | 27.87M | 26.03M | 25.07M | 23.58M | 22.41M | 21.5M | 18.94M | 20.42M | 19.38M | 17.53M | 15.84M | 15.22M | 12.77M | 12.61M | 11.55M | 15.72M | 13.16M | 12.36M | 9.37M | 8.49M | 8.49M | 5.08M | 5.08M | 4.1M | 4.1M |
| Research and Development Revenue Growth | +20.79% | +14.32% | +7.08% | +3.84% | +6.28% | +5.23% | +4.24% | +13.52% | -7.26% | +5.37% | +10.57% | +10.66% | +4.05% | +19.22% | +1.30% | +9.09% | -26.49% | +19.47% | +6.46% | +31.84% | +10.38% | n/a | +67.27% | n/a | +23.71% | n/a | n/a |